Validación pronóstica según los criterios de la GesEPOC 2017
Cabrera López, C. ; Casanova Macario, C. ; Marín Trigo, J.M. (Universidad de Zaragoza) ; de-Torres, J.P. ; Torres, R.S. ; González, J.M. ; Polverino, F. ; Divo, M. ; Pinto Plata, V. ; Zulueta, J. ; Callejas, F.J. ; Celli, B.
Resumen: Introduction: The Spanish COPD guidelines (GesEPOC) have been recently modified. The aim of this study is to assess this revision and evaluate the prognosis of patients according to the new classification of severity.
Methods: A total of 700 COPD patients (83.9% men) were prospectively followed up for a mean period of 5 years in tertiary hospitals in Spain and the USA. Anthropometric data, lung function tests, dyspnea (according to the mMRC scale), BODE and Charlson index were collected. We calculated mortality at 5 years following the risk criteria proposed by the new GesEPOC.
Results: Mean age was 66 ± 9.6 years and mean FEV1% was 59.7 ± 20.2. The proportion of patients in the low-risk group was 40.43%. Patients in the high-risk group had a significantly higher BODE index than those in the low-risk group (2.92 ± 0, 66 vs. 0.52 ± 1.91, p < 0.001), while the Charlson index score was similar in both groups. Mortality at 60 months was significantly higher in the high-risk group (31.7% vs. 15.5%, p < 0.001). Dyspnea and FEV1% were also independent predictors of mortality (p < 0.001), and neither was inferior to the risk classification proposed by GesEPOC.
Conclusions: The new severity index proposed by GesEPOC accurately predicts 5-year mortality. However, dyspnea and FEV1% have the same strength in predicting mortality.
Idioma: Español
DOI: 10.1016/j.arbres.2018.12.002
Año: 2019
Publicado en: Archivos de Bronconeumologia 55, 8 (2019), 409-413
ISSN: 0300-2896
Factor impacto JCR: 4.957 (2019)
Categ. JCR: RESPIRATORY SYSTEM rank: 11 / 64 = 0.172 (2019) - Q1 - T1
Factor impacto SCIMAGO: 0.287 - Pulmonary and Respiratory Medicine (Q3)
Tipo y forma: Artículo (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.
Exportado de SIDERAL (2020-07-16-09:29:07)
Visitas y descargas
Methods: A total of 700 COPD patients (83.9% men) were prospectively followed up for a mean period of 5 years in tertiary hospitals in Spain and the USA. Anthropometric data, lung function tests, dyspnea (according to the mMRC scale), BODE and Charlson index were collected. We calculated mortality at 5 years following the risk criteria proposed by the new GesEPOC.
Results: Mean age was 66 ± 9.6 years and mean FEV1% was 59.7 ± 20.2. The proportion of patients in the low-risk group was 40.43%. Patients in the high-risk group had a significantly higher BODE index than those in the low-risk group (2.92 ± 0, 66 vs. 0.52 ± 1.91, p < 0.001), while the Charlson index score was similar in both groups. Mortality at 60 months was significantly higher in the high-risk group (31.7% vs. 15.5%, p < 0.001). Dyspnea and FEV1% were also independent predictors of mortality (p < 0.001), and neither was inferior to the risk classification proposed by GesEPOC.
Conclusions: The new severity index proposed by GesEPOC accurately predicts 5-year mortality. However, dyspnea and FEV1% have the same strength in predicting mortality.
Idioma: Español
DOI: 10.1016/j.arbres.2018.12.002
Año: 2019
Publicado en: Archivos de Bronconeumologia 55, 8 (2019), 409-413
ISSN: 0300-2896
Factor impacto JCR: 4.957 (2019)
Categ. JCR: RESPIRATORY SYSTEM rank: 11 / 64 = 0.172 (2019) - Q1 - T1
Factor impacto SCIMAGO: 0.287 - Pulmonary and Respiratory Medicine (Q3)
Tipo y forma: Artículo (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.Exportado de SIDERAL (2020-07-16-09:29:07)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos
Registro creado el 2020-02-04, última modificación el 2020-07-16